Na succes in de oncologie, uitgebreid realtime dataplatform om een betere betrokkenheid te stimuleren met wetenschappelijke, klinische en digitale leiders op therapeutische gebieden

BARCELONA, Spanje– (BUSINESS WIRE) – Veeva Systems (NYSE: VEEV) heeft vandaag Veeva Link aangekondigd voor 11 nieuwe therapeutische gebieden, waaronder bacteriële infecties, cardiologie, dermatologie, endocrinologie, gastro-enterologie, hepatologie, nefrologie, neurologie, luchtwegen, reumatologie en virologie . Veeva Link verbindt miljoenen wetenschappelijke, klinische en digitale activiteiten om commerciële en medische teams real-time klantinformatie te bieden over belangrijke mensen per therapeutisch gebied. De toevoeging van 11 nieuwe therapeutische gebieden bouwt voort op het succes van Veeva Link for Oncology, dat vandaag wordt gebruikt door 6 van de 10 grootste farmaceutische bedrijven.

Veeva Link Expands to 11 New Therapeutic Areas

Following success in oncology, expanded real-time data platform to help drive better engagement with scientific, clinical, and digital leaders across therapeutic areas

BARCELONA, Spain–(BUSINESS WIRE)– Veeva Systems (NYSE: VEEV) today announced Veeva Link for 11 new therapeutic areas, including bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology. Veeva Link connects millions of scientific, clinical, and digital activities to provide commercial and medical teams real-time customer intelligence on key people by therapeutic area. The addition of 11 new therapeutic areas builds upon the success of Veeva Link for Oncology, which is used today by 6 of the top 10 largest pharmaceutical companies.

“There is an increasingly complex ecosystem of healthcare decision-makers shaping the research and commercialization of innovative specialty medicines,” said Killian Weiss, general manager for Veeva Link. “Veeva Link provides real-time customer intelligence for life sciences to partner with the right scientific, clinical, and digital leaders for improved research and patient care.”

“We use Veeva Link for Oncology and like it because it gives our field teams intelligence on people, institutions, and developments throughout the oncology healthcare community all in one place,” said Hatem Tolba, director of sales analytics at Oncopeptides, Inc., a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.

Veeva Link provides real-time information on key people, including areas of expertise, peer collaborations, speaking engagements, social media activity, and clinical trial activity. Information is sourced from more than 50,000 sources and maintained in real-time through both advanced technology and human curation. With Veeva Link, field teams can now have fast, complete, and accurate intelligence from planning to execution.

Veeva Link solutions for the 11 new therapeutic areas are planned for availability starting in March 2021. To learn how Veeva Link delivers real-time customer intelligence to drive better customer engagement, attend the session at Veeva Commercial & Medical Europe Summit Online, 17 Nov., 2020. The online event is open to life sciences industry professionals. Register and see the full agenda at veeva.com/Summit.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006087/en/

Contacts

Roger Villareal

Veeva Systems

925-264-8885

roger.villareal@veeva.com